标题
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 17, Pages 6176
出版商
MDPI AG
发表日期
2020-08-27
DOI
10.3390/ijms21176176
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
- (2020) M. Chalabi et al. ANNALS OF ONCOLOGY
- Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
- (2020) Leitao Sun et al. Scientific Reports
- Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
- (2020) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
- (2020) Xueping Wang et al. Molecular Cancer
- Sex-associated molecular differences for cancer immunotherapy
- (2020) Youqiong Ye et al. Nature Communications
- Cytokines regulate the antigen-presenting characteristics of human circulating and tissue-resident intestinal ILCs
- (2020) Anna Rao et al. Nature Communications
- Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy
- (2020) Michael F. Coleman et al. Cancers
- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- PTEN Mutations Trigger Resistance to Immunotherapy
- (2019) Feixiong Cheng et al. TRENDS IN MOLECULAR MEDICINE
- PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua
- (2019) Paola Vacca et al. Mucosal Immunology
- Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD‐1 receptor
- (2019) Nicola Tumino et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
- (2019) Marilina García-Aranda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy.
- (2019) Giulia Galli et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer: Is There Room for Reinvestigation?
- (2019) Myung-Ju Ahn Journal of Thoracic Oncology
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Helper-like innate lymphoid cells and cancer immunotherapy
- (2019) Adeline Crinier et al. SEMINARS IN IMMUNOLOGY
- Physical Activity Plus Energy Restriction Prevents 4T1.2 Mammary Tumor Progression, MDSC Accumulation, and an Immunosuppressive Tumor Microenvironment
- (2019) William J. Turbitt et al. Cancer Prevention Research
- First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
- (2019) Neeta Somaiah et al. CLINICAL CANCER RESEARCH
- Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
- (2019) Shin Hye Yoo et al. Scientific Reports
- Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors
- (2019) Andy S. Ding et al. Frontiers in Immunology
- Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions
- (2019) Francesca Romana Mariotti et al. Frontiers in Immunology
- Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases
- (2019) Chuan Huang et al. JOURNAL OF AUTOIMMUNITY
- Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
- (2019) Shixiang Wang et al. MOLECULES
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice
- (2019) Sarah Lévesque et al. OncoImmunology
- The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
- (2019) Douglas Donnelly et al. Journal for ImmunoTherapy of Cancer
- VISTA is an acidic pH-selective ligand for PSGL-1
- (2019) Robert J. Johnston et al. NATURE
- Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
- (2019) Spencer C. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
- (2019) Xianguang Bai et al. OncoTargets and Therapy
- Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
- (2019) Jonathan A. Trujillo et al. Journal for ImmunoTherapy of Cancer
- Harnessing tumor-associated macrophages as aids for cancer immunotherapy
- (2019) Xiaolei Li et al. Molecular Cancer
- WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
- (2019) Elena Martin-Orozco et al. Frontiers in Immunology
- T-Regulatory Cells In Tumor Progression And Therapy
- (2019) Amit Verma et al. Cancer Management and Research
- Regulatory T cells: a potential target in cancer immunotherapy
- (2018) Kohei Shitara et al. Annals of the New York Academy of Sciences
- Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
- (2018) Xue Li et al. CANCER LETTERS
- Do immune checkpoint inhibitors perform identically in patients with weight extremes?
- (2018) Elie El Rassy et al. Immunotherapy
- Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
- (2018) Yingcheng Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells
- (2018) Virginia K. Clements et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Nivolumab Plus Erlotinib in Patients With EGFR -Mutant Advanced NSCLC
- (2018) Scott Gettinger et al. Journal of Thoracic Oncology
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Next generation immune-checkpoints for cancer therapy
- (2018) Chiara Donini et al. Journal of Thoracic Disease
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
- (2018) Magalie Dosset et al. OncoImmunology
- Synopsis of arachidonic acid metabolism: A review
- (2018) Violette Said Hanna et al. Journal of Advanced Research
- Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
- (2018) Eiji Shinozaki et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8+ T cells and facilitates anti-PD-1 therapy
- (2018) Partha S. Chowdhury et al. Cancer Immunology Research
- Interferon gamma in cancer immunotherapy
- (2018) Ling Ni et al. Cancer Medicine
- Not All Immune Checkpoints Are Created Equal
- (2018) Annika De Sousa Linhares et al. Frontiers in Immunology
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Cytokines in clinical cancer immunotherapy
- (2018) Pedro Berraondo et al. BRITISH JOURNAL OF CANCER
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- (2018) Stéphane Champiat et al. Nature Reviews Clinical Oncology
- Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist
- (2018) Fanny Polesso et al. Cancer Immunology Research
- Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis
- (2018) Basit Jabbar et al. Frontiers in Immunology
- Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
- (2018) Antonino Grassadonia et al. Journal of Clinical Medicine
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity
- (2017) Ryu Watanabe et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-1 regulates KLRG1+group 2 innate lymphoid cells
- (2017) Samuel Taylor et al. JOURNAL OF EXPERIMENTAL MEDICINE
- OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
- (2017) Solange Peters et al. Journal of Thoracic Oncology
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Emerging targets in cancer immunotherapy
- (2017) Samantha Burugu et al. SEMINARS IN CANCER BIOLOGY
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment
- (2017) Jie Miao et al. Oncotarget
- Acute Dietary Restriction Acts via TOR, PP2A, and Myc Signaling to Boost Innate Immunity in Drosophila
- (2017) Jung-Eun Lee et al. Cell Reports
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
- (2017) Rajeev K. Shrimali et al. Cancer Immunology Research
- PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
- (2017) Carmen Stecher et al. Frontiers in Immunology
- Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors
- (2017) Eva M. Palsson-McDermott et al. Frontiers in Immunology
- Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
- (2017) Arthur E. Frankel et al. NEOPLASIA
- NSAIDs Use and Reduced Metastasis in Cancer Patients: results from a meta-analysis
- (2017) Xiaoping Zhao et al. Scientific Reports
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Tumor antigens in human cancer control
- (2016) Sander Kelderman et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity
- (2016) Stefano Di Biase et al. CANCER CELL
- Microbiome and Anticancer Immunosurveillance
- (2016) Laurence Zitvogel et al. CELL
- Caloric Restriction Leads to Browning of White Adipose Tissue through Type 2 Immune Signaling
- (2016) Salvatore Fabbiano et al. Cell Metabolism
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
- (2016) Z. Ma et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
- (2016) Jon Bjoern et al. CYTOTHERAPY
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- The role of neoantigens in response to immune checkpoint blockade
- (2016) Nadeem Riaz et al. INTERNATIONAL IMMUNOLOGY
- Hypoxia-inducible factors: a central link between inflammation and cancer
- (2016) Daniel Triner et al. JOURNAL OF CLINICAL INVESTIGATION
- Dietary restriction improves repopulation but impairs lymphoid differentiation capacity of hematopoietic stem cells in early aging
- (2016) Duozhuang Tang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway
- (2016) Yong Yu et al. NATURE
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wnt signaling in cancer
- (2016) T Zhan et al. ONCOGENE
- Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma
- (2016) Stefani Spranger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Obesity Paradox in Cancer: a Review
- (2016) Hannah Lennon et al. Current Oncology Reports
- PKM2 and cancer: The function of PKM2 beyond glycolysis
- (2016) GAOCHAO DONG et al. Oncology Letters
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- The concept of immune surveillance against tumors: The first theories
- (2016) Domenico Ribatti Oncotarget
- Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
- (2016) G. de Velasco et al. Cancer Immunology Research
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
- (2015) E. K. Moon et al. CLINICAL CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
- (2015) Cheng Lin et al. Clinical Lung Cancer
- Proton pump inhibitors alter the composition of the gut microbiota
- (2015) Matthew A Jackson et al. GUT
- Metabolic Reprogramming of Immune Cells in Cancer Progression
- (2015) Subhra K. Biswas IMMUNITY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- High Mitochondrial Respiration and Glycolytic Capacity Represent a Metabolic Phenotype of Human Tolerogenic Dendritic Cells
- (2015) Frano Malinarich et al. JOURNAL OF IMMUNOLOGY
- Differential impact of obesity and diabetes mellitus on survival after liver resection for colorectal cancer metastases
- (2015) Sousana Amptoulach et al. JOURNAL OF SURGICAL RESEARCH
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- (2015) Andrew B Sharabi et al. LANCET ONCOLOGY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
- (2015) E. Vacchelli et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
- (2015) Nicolas van Baren et al. Frontiers in Immunology
- BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
- (2015) Cara L Haymaker et al. OncoImmunology
- New and emerging factors in tumorigenesis: an overview
- (2015) Suwon Kim Cancer Management and Research
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
- (2015) Stefanie N. Linch et al. Frontiers in Oncology
- PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma
- (2015) Wei-Ren Liu et al. Oncotarget
- Pathways to Tumorigenesis—Modeling Mutation Acquisition in Stem Cells and Their Progeny
- (2015) Rina Ashkenazi et al. NEOPLASIA
- Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis
- (2014) Sabrina Schlesinger et al. CANCER CAUSES & CONTROL
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging
- (2014) Michelle Farazi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
- (2014) T. Chodon et al. CLINICAL CANCER RESEARCH
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
- (2014) P. F. Robbins et al. CLINICAL CANCER RESEARCH
- Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
- (2014) S. Nag et al. CURRENT MEDICINAL CHEMISTRY
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
- (2014) Nicole Joller et al. IMMUNITY
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts
- (2014) Pragya Srivastava et al. LEUKEMIA RESEARCH
- Inducible costimulator facilitates T-dependent B cell activation by augmenting IL-4 translation
- (2014) Mathieu Gigoux et al. MOLECULAR IMMUNOLOGY
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- (2014) John C. Morris et al. PLoS One
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
- (2014) S. L. Highfill et al. Science Translational Medicine
- Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
- (2014) Sabrina Ceeraz et al. ARTHRITIS RESEARCH & THERAPY
- Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy
- (2014) Bronwen R. Burton et al. Nature Communications
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy
- (2014) Young J Kim OncoImmunology
- Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
- (2013) Matthew D. Vesely et al. Annals of the New York Academy of Sciences
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer
- (2013) Kouichirou Aida et al. CANCER SCIENCE
- Adipokines in obesity
- (2013) Viviane de Oliveira Leal et al. CLINICA CHIMICA ACTA
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Macrophage biology in development, homeostasis and disease
- (2013) Thomas A. Wynn et al. NATURE
- MHC Class II Antigen Presentation by Dendritic Cells Regulated through Endosomal Sorting
- (2013) T. ten Broeke et al. Cold Spring Harbor Perspectives in Biology
- Mechanisms of Obesity-Induced Inflammation and Insulin Resistance: Insights into the Emerging Role of Nutritional Strategies
- (2013) Maeve A. McArdle et al. Frontiers in Endocrinology
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes
- (2012) A. Calcinotto et al. CANCER RESEARCH
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- Modulation of GITR for cancer immunotherapy
- (2012) David A Schaer et al. CURRENT OPINION IN IMMUNOLOGY
- Adiponectin: mechanistic insights and clinical implications
- (2012) A. T. Turer et al. DIABETOLOGIA
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis and modulates key biomarkers in vivo
- (2012) C Eberlein et al. ONCOGENE
- Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa
- (2012) E. T. Clambey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
- (2011) Oliver Kepp et al. CANCER AND METASTASIS REVIEWS
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM
- (2010) Theresa L. Murphy et al. Annual Review of Immunology
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
- (2010) Michael Croft Annual Review of Immunology
- Macrophage Expression of Hypoxia-Inducible Factor-1 Suppresses T-Cell Function and Promotes Tumor Progression
- (2010) A. L. Doedens et al. CANCER RESEARCH
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients
- (2010) Hyunji Lee et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
- (2010) Adam D. Cohen et al. PLoS One
- Radiation-induced cell death mechanisms
- (2010) David Eriksson et al. TUMOR BIOLOGY
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
- (2009) Kent S. Boles et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation
- (2009) Guifang Cai et al. IMMUNOLOGICAL REVIEWS
- Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling
- (2009) Carsten Linnemann et al. IMMUNOLOGY
- Innate immunity
- (2009) Stuart E. Turvey et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right
- (2009) C. E. Ruby et al. JOURNAL OF IMMUNOLOGY
- Unconventional ligand activation of herpesvirus entry mediator signals cell survival
- (2009) T. C. Cheung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
- (2008) Li Yang et al. CANCER CELL
- TGFβ in Cancer
- (2008) Joan Massagué CELL
- Endocytosis mechanisms and the cell biology of antigen presentation
- (2008) Sven Burgdorf et al. CURRENT OPINION IN IMMUNOLOGY
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started